Elephants have roughly a hundred times more cells than we do. They get cancer at maybe a quarter the rate. The difference is mostly TP53 copy number and a re-functionalized pseudogene called LIF6 — the elephant's molecular kill-switch. So we built a chimera. NKG2D out front (the receptor your NK cells use to spot stressed cells), elephant LIF6 in the back (the mitochondrial puncher). One construct. AAV9 delivery. Tumor-restricted by design.
Everything below is computational right now. No mice, no patients, no published paper. The wet-lab program kicks off in Q3. We're publishing the in silico methodology open under CC BY 4.0 because external critique now is much cheaper than after a failed in vivo.
Across 8 species, from naked mole rat to blue whale, cancer follows the same four-phase program. Block any phase and cancer loses.
Reactivate embryonic proliferation programs.
Build immunosuppressive TME — Tregs, MDSCs, PD-L1.
Enter dormancy when threatened — chemo resistance.
Phoenix Rising: apoptotic debris hijacks PGE2 → growth.
We took the human gene that detects cancer (KLRK1/NKG2D) and wired it to the elephant gene that kills cancer (LIF6 — the "zombie gene"). The result is one molecule that sees a tumor and triggers mitochondrial apoptosis on contact.
NKG2D ectodomain binds MICA/MICB stress ligands — present only on cancer cells, never on healthy tissue.
Patient-specific genotype variant rs1049174 GG (HNK1/HNK1) gives 1.5× NK cytotoxicity. Personalized at the genome level.
LIF6 — the elephant zombie gene reactivated by TP53 — punctures mitochondrial membranes via BAK. Pure apoptosis, no inflammation.
mRNA-LNP. Same technology as COVID vaccines. $500–$2,000 per dose at scale. Or as armed CAR-NK for high-value indications.
Every layer of biology tested in silico — from immunodeficient mouse to full human physiology to evolutionary ladder across 8 species. The signal is consistent.
Designed and built the entire OMNIKILL platform — 6,500 lines of simulation code, 28 charts, 5 reports, 1 universal cancer pattern, and the NKG2D-LIF6 chimeric construct ready for synthesis. Single founder, full stack, in 18 months.
Pre-clinical, GMP manufacturing, IND-enabling tox, and Phase I basket trial across 6 cancer types. Patient-specific PGx-aware therapy design.
artem@nightboxllc.com →Engagement areas
Specific organization mentions available on request under NDA.